TGTX250117C28000
- 2.60
- +1.10+73.33%
TG Therapeutics Newsroom
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
TG Therapeutics Reports Strong Revenue and Future Goals
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
What's Going On With TG Therapeutics Stock Tuesday?
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M
Express News | TG Therapeutics Inc Qtrly Briumvi U.S. Net Product Rev Expected to Be $103.6 Mln
TG Therapeutics Sees 2025 Rev $540M >TGTX
Express News | TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
TG Therapeutics Price Target Raised to $10 From $9 at BofA
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Express News | TG Therapeutics Inc : BofA Global Research Raises Price Objective to $10 From $9
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)